New Mayzent data published in Neurology shows sustained effect in delaying disability for up to five years in secondary progressive multiple sclerosis .- Novartis
Novartis announced new Mayzent (siponimod) data in the April supplemental issue of Neurology, the medical journal of the American Academy of Neurology. The data build on existing clinical… read more.